Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB and Biogen Idec have established a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis.
Subscribe to our email newsletter
Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million dollars. Furthermore, Biogen Idec will contribute significantly to clinical costs for phase II and phase III studies. All commercialization costs and profits will be shared equally.
“We are always looking to enhance and expand our arsenal in the fight against multiple sclerosis (MS),” said Al Sandrock, senior vice president of neurology R&D for Biogen Idec. “Another effective oral therapy would augment Biogen Idec's broad portfolio of products and potential therapies in development for this debilitating disease.”
CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter phase II clinical trials next year.
Biogen has developed two other treatments for MS, namely Avonex and Tysabri.